CAMBRIDGE, Mass. and NESS ZIONA, Israel, May 08, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the Company will host a conference call and a live audio webcast on Monday, May 15th, 2023, at 8:00 a.m. ET, to report first quarter 2023 financial results and provide business updates.
To participate in the conference call, please dial 1-877-407-0724 (U.S.) or 1-201-389-0898 (International). The live and archived webcast will be available in the Investors section of the Company’s website at www.biomx.com.
About BiomX
BiomX is a clinical-stage company developing both natural and engineered phage cocktails designed to target and destroy bacteria in the treatment of chronic diseases. BiomX discovers and validates proprietary bacterial targets and customizes phage compositions against these targets. For more information, please visit www.biomx.com.
BiomX, Inc.
Anat Primovich
Corporate Project Manager
+97250-6977228
This email address is being protected from spambots. You need JavaScript enabled to view it.
Investor Relations:
LifeSci Advisors, LLC
John Mullaly
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$0.41 |
Daily Change: | 0.02 6.28 |
Daily Volume: | 123,274 |
Market Cap: | US$22.530M |
April 03, 2024 March 18, 2024 March 06, 2024 |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREC4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB